• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Celestia S. Higano, Paul Schellhammer, +5 authors Mark Walter Frohlich
  • Medicine
  • Cancer
  • 2009 (First Publication: 15 August 2009)
  • BACKGROUND Sipuleucel-T is an investigational active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. The safety and efficacy of sipuleucel-T wasContinue Reading
  • Fadlo R. Khuri, John Nemunaitis, +13 authors David H. Kirn
  • Medicine
  • Nature Medicine
  • 2000 (First Publication: 1 August 2000)
  • ONYX-015 is an adenovirus with the E1B 55-kDa gene deleted, engineered to selectively replicate in and lyse p53-deficient cancer cells while sparing normal cells. Although ONYX-015 and chemotherapyContinue Reading
  • C. Casey Cunningham, Sunil Chada, +10 authors John Nemunaitis
  • Biology, Medicine
  • Molecular therapy : the journal of the American…
  • 2005
  • The melanoma differentiation-associated gene-7 (mda-7; approved gene symbol IL24) is a tumor suppressor gene whose expression induces selective apoptosis in tumor cells. To characterize the safetyContinue Reading
  • Dung Thi Kim Le, Dirk G. Brockstedt, +19 authors Daniel A Laheru
  • Medicine
  • Clinical Cancer Research
  • 2011 (First Publication: 6 December 2011)
  • Purpose: Listeria monocytogenes (Lm)-based vaccines stimulate both innate and adaptive immunity. ANZ-100 is a live-attenuated Lm strain (Lm ΔactA/ΔinlB). Uptake by phagocytes in the liver results inContinue Reading
  • John Nemunaitis, Alex W. Tong, +12 authors Toshiyoshi Fujiwara
  • Biology, Medicine
  • Molecular therapy : the journal of the American…
  • 2010 (First Publication: 1 February 2010)
  • A phase I clinical trial was conducted to determine the clinical safety of Telomelysin, a human telomerase reverse transcriptase (hTERT) promoter driven modified oncolytic adenovirus, in patientsContinue Reading
  • John Nemunaitis, Daniel H. Sterman, +8 authors Kristen M. Hege
  • Medicine
  • Journal of the National Cancer Institute
  • 2004 (First Publication: 18 February 2004)
  • To evaluate the feasibility, safety, and efficacy of vaccination with autologous tumor cells genetically modified with an adenoviral vector (Ad-GM) to secrete human granulocyte-macrophageContinue Reading
  • Robert S. DiPaola, John Rinehart, +14 authors Siu-Long Yao
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2002 (First Publication: 1 April 2002)
  • PURPOSE To evaluate safety and pharmacokinetics (PK), and determine the recommended dose for efficacy studies, of L-377202, a novel peptide conjugate of doxorubicin (Dox) that releases the activeContinue Reading